COPD Prescribing Guidelines

Size: px
Start display at page:

Download "COPD Prescribing Guidelines"

Transcription

1 South Staffordshire Area Prescribing Group COPD Prescribing Guidelines Inhaler choices in this guideline are different from previous versions produced by the APG. It is not expected patients controlled on established therapy will be changed without clinical assessment. All NEW patients should be initiated on inhaler therapy as per these guidelines. Written by MMSESSP Review December 2016

2 COPD Prescribing Guidelines This guideline is intended for use to aid diagnosis in patients with a suspected diagnosis of a COPD, and in patients with a confirmed diagnosis of COPD. In the latter group it is intended to direct management including prescribing. It is aimed primarily at cost-effective prescribing, and will be reviewed annually as evidence is rapidly emerging in this field COPD is characterised by airflow obstruction. The airflow obstruction is usually progressive, not fully reversible and does not change markedly over several months. The disease is predominately caused by smoking. Diagnosis 1. Suspect COPD if: Any of the following indicators are present in an individual over 35 years old. Dyspnoea that is - Progressive - Characteristically worse with exercise - Persistent. Wheezing Chronic cough may be intermittent, and/or unproductive Chronic sputum production any pattern of chronic sputum production may indicate COPD History of exposure to risk factors tobacco smoke/ smoke from cooking and heating fuels/ occupational dusts and chemicals AND do not have clinical features of Asthma: Chronic unproductive cough Significantly variable breathlessness Night-time wakening with breathlessness and/or wheeze Significant diurnal or day-to-day variability of symptoms 2. Spirometry Test: Spirometry is required to establish a diagnosis of COPD. Post bronchodilator spirometry demonstrates: FEV 1 /FVC <70% NB. The presence of multiple key indicators increases the probability of diagnosis of COPD. Quality assessment 3 blows with FEV 1 values within 100ml of one another FVC obtained after blowing out 6 seconds Is it airflow obstruction? FEV 1 / FVC < Interpreting Spirometry Severity assessment Make sure it isn t asthma* FEV 1 > 80% Mild A Check reversibility to salbutamol 50-80% Moderate B >400ml = asthma 30-50% Severe C Check PEFR variation over 2/52 < 30% Very Severe D >20% = asthma

3 COPD Prescribing Guidelines Possible Alternative Diagnosis Asthma Congestive Heart Failure Bronchiectasis Tuberculosis Obliterative Bronchiolitis Diffuse Panbronchiolitis Lung Cancer (Chest X Ray- If 3 week history of cough and /or increasing breathlessness) Full blood count to identify anaemia or polycythaemia Check inhaler technique Encourage all patients to stop smoking, beneficial at all ages. Offer annual pneumococcal and influenza vaccinations. Management of Stable COPD Refer to pulmonary rehabilitation when mmrc score is 2 (or for GOLD classification B-D as per GOLD guidelines) Promote use of self-management plan and rescue packs. Template self-management plan can be found at: [Link for Self-Management Plan] Screen for common comorbidities e.g. IHD, HF, anxiety, and depression. Consider referral to the rest of the multidisciplinary team e.g. Community respiratory team / Consultant led respiratory clinic, physiotherapists, dietician (follow current malnutrition guidelines if BMI/MUST score is low or high respectively), occupational therapy, social services, and palliative care teams. Where medication is initiated for persistent breathlessness monitor and discontinue if no improvement Refer for oxygen assessment when O2 saturations are less than or equal to 92% breathing air.

4 Assessment of COPD using GOLD Classification COPD Prescribing Guidelines STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed instrument that is a comprehensive measure of symptoms and complements existing approaches to assessing COPD. Determine whether patient has less symptoms (<10) or more symptoms (>10) if using CAT scale. Assess mmrc (modified Medical Research Council Questionnaire) providing an assessment of impact of dyspnoea. Determine if the patient is less breathlessness (0-1) or more breathlessness ( 2). STEP 2: Assess risk of exacerbations by the following method: Assess the number of exacerbations the patient has had within the previous 12 months Determine whether the patient has had one or more hospitalisation in the previous year for a COPD exacerbation Use spirometry to determine if patient is high risk (FEV 1 <50%) or low risk (FEV 1 50%) In some patients these three ways of assessing the risk of exacerbations will not lead to the same level of risk; in this case, the risk should be determined by the method indicating high risk Determine Gold Classification and treatment according to Table 1 GOLD Classification attempt to class patients based on their risks of exacerbation.

5 COPD Prescribing Guidelines Table 1: Gold Classification & Respective Drug Treatment Patients can start in any classification and can migrate between groups, therefore regular assessment is essential (See Appendix 2 for in list of inhaler brands, dosing, costs & images) CAT <10 STEP 1: Symptom Assessment CAT 10 Number of Exacerbations in previous 12 months Hospitalisation in previous 12 months FEV 1 mmrc 0-1 Low risk Gold A mmrc 2 Moderate risk Gold B STEP 2: Risk Assessment 1 2 zero 1 50% Predicted < 50% Predicted Step 1: SABA or SAMA (NB SABA can continue as reliever through all steps) Step 2: LABA Severe risk Gold C Step 1: ICS/LABA (if LAMA tried) Or Step 1: LAMA (if LAMA naïve) Step 2: LABA/ LAMA combination Step 1: LABA (if LABA naïve) Or Step 1: LAMA Step 2: LABA/ LAMA combination suitable where severe breathlessness Very Severe risk Gold D Triple therapy if patient has progressed from C or B. OR LABA/LAMA combination if treatment naïve Or ICS/LABA & Theophylline Or LAMA & Theophylline Inhaler choices for management of Stable patients try to maintain device consistency if possible LABA LAMA LABA/LAMA LABA/ICS Easyhaler Formoterol Seebri Breezhaler Anoro Ellipta Fostair MDI Onbrez Breezhaler 1 Incruse Ellipta Duaklir Genuair * DuoResp Spiromax Eklira Genuair* Ultibro Breezehaler Relvar Ellipta Key: 1. Starting dose 150mcg, increased to 300mcg if needed. * Twice daily preparation therefore not suitable for all patients LAMA caution use in patients with cardiac arrhythmias, recent hospitalisation with cardiac background e.g. MI, HF, etc. These are class effects

6 Managing COPD Exacerbations COPD Prescribing Guidelines Considerations: (circle as appropriate) Favours specialist treatment Favours treatment at home Able to cope at home: No Yes Breathlessness: Severe Mild General condition: Poor / deteriorating Good Level of activity: Poor / confined to bed Good Cyanosis: Yes No Worsening Peripheral Oedema: Yes No Level of consciousness: Impaired Normal LTOT currently received: Yes No Social circumstances: Living alone / not coping Good Acute confusion: Yes No Rapid rate of onset: Yes No Significant morbidity: Yes No SaO 2 <90%: Yes No Decide where to treat: Hospital Home

7 COPD Prescribing Guidelines ACUTE MANAGEMENT (at home) Steroids - Prednisolone 30mg daily for 7-14 days then stop 1st line antibiotic - Amoxicillin 500mg three times a day for 5 days; OR [Penicillin allergy] - Clarithromycin 500mg twice daily for 5 days [Significant drug Interaction] - Theophylline halve dose and - Simvastatin stop/reduce dose - Consider other interactions 2nd line antibiotic If resistant - Doxycycline 200mg immediately then 100mg daily for a further 4 days - Co-Amoxiclav 625mg three times a day for 5 days (consider C.Diff risk) Optimise treatment - Increase SABA to 2-8 puffs up to 4 hourly (watch for side effects e.g. tremor) If no improvement at one week or deterioration in symptoms, clinician to consider referral or advice from community COPD consultant / team. PREVENTION OF FUTURE EXACERBATIONS Refer to pulmonary rehabilitation Optimise inhaled therapy in line with GOLD standards above Carbocisteine - Two or more exacerbations in the next 12 month, consider adding in Carbocisteine 750mg twice daily (maintenance dose) especially if chronic productive cough - Review on-going need/ benefit and stop if ineffective after 4 6 weeks of treatment

8 COPD Prescribing Guidelines References: 1. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) Available from: accessed on 8 th April NICE 2010 COPD guidelines 3. IMPRESS Guide to the relative value of COPD interventions July all drug files accessed 5. British National Formulary, version 68, BMA Mims Online accessed May 2015 ACKNOWLEDGEMENTS TO ALICE TURNER AND PAN BIRMINGHAM APC

9 Appendices COPD Prescribing Guidelines Appendix 1 - mmrc Modified Research Council Questionnaire Grade Description of Breathlessness 0 I only get breathless with strenuous exercise. 1 I get short of breath when hurrying on level ground or walking up a slight hill. 2 On level ground, I walk slower than people of the same age because of breathlessness, or have to stop for breath when walking at my own pace. 3 I stop for breath after walking about 100 yards or after a few minutes on level ground. 4 I am too breathless to leave the house or I am breathless when dressing CAT Test Online - or Direct link to CAT-test online: [Link]

10 Appendix 2 Inhaler Profile COPD Prescribing Guidelines Prescribe all inhalers by Brand Name Drug Strength Brand Picture Type of Device Separate Spacer Dose & Frequency Cost ** Salamol MDI Aerochamber Plus/Volumatic Spacer 1.46 Ventolin MDI Aerochamber Plus/Volumatic Spacer 1.50 SABA (Short Acting Beta2 Agonist) Salbutamol 100 mcg Airomir MDI Aerochamber Plus Airomir Autohaler DPI - 2 puffs when required Salamol Easi- Breathe MDI Salbutamol Easyhaler DPI Terbutaline 500 mcg Bricanyl Turbohaler DPI - 1 puff, up to four times a day 6.92 (100 doses) SAMA (Short Acting Anti- Muscarinic) Ipratropium 20 mcg Atrovent MDI Aerochamber Plus 1 puff, up to four times a day 5.56 LABA (Long Acting Beta2 Agonist) Formoterol 12 mcg Easyhaler Formoterol DPI - 1 puff Twice daily Device will last two months (120 doses)

11 COPD Prescribing Guidelines Indacaterol 150 mcg Onbrez Breezhaler & Caps DPI - 1 puff Once daily (30 doses) LAMA (Long Acting Anti- Muscarinic) Glycopyrronium 50 mcg Seebri Breezhaler & Caps DPI - 1 puff Once daily Umeclidinium 55 mcg Incruse Ellipta DPI - 1 puff Once daily (30 doses) (30 doses) Aclidinium 322 mcg Eklira Genuair DPI - 1 puff Twice daily (60 doses) LABA/ LAMA combination (Long Acting Antimuscarinic & Long Acting Beta2 Agonist) Vilanterol/ Umeclidinium Indacaterol/ Glycopyrronium Formoterol/ Aclidinium 22 mcg / 55 mcg 110 mcg / 50 mcg 12 mcg / 340 mcg Anoro Ellipta DPI - 1 puff Once daily Ultibro Breezhaler & Caps Duaklir Genuair DPI - DPI - 1 puff Once daily 1 puff Twice daily (30 doses) (30 doses) (60 doses) LABA/ICS combination (Long Acting Beta2 Agonist & Inhaled Corticosteroid) Formoterol/ Beclometasone Formoterol/ Budesonide Vilanterol/ Fluticasone 6 mcg / 100 mcg 9 mcg / 320 mcg 22 mcg / 92 mcg Fostair* MDI Aerochamber Plus DuoResp Spiromax DPI - Relvar Ellipta DPI - 2 puffs Twice daily 1 puff Twice daily 1 puff Once daily (120 doses) (60 doses) (30 doses) Note: - DPI = Dry-powder Inhaler - *Fostair NEXThaler for asthma only - MDI = Metered Dose Inhaler - Cost per device - Spacers - wash weekly, do NOT wipe dry. Replace every six to 12 months. - ** prices taken from Mims online accessed May 2015

12 Appendix 3: COPD intervention Value Pyramid COPD Prescribing Guidelines

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Guidelines All healthcare professionals(hcps) caring for patients with asthma Version

More information

Greater Manchester COPD Management Plan

Greater Manchester COPD Management Plan Greater Manchester COPD Management Plan Inhaler therapy options for patients with COPD Non-pharmacological options for ALL patients, consider at all stages (please see page 3): Inhaler technique Encourage

More information

CHARM COPD Guidelines for the diagnosis and. the Borough of City and Hackney

CHARM COPD Guidelines for the diagnosis and. the Borough of City and Hackney CHARM COPD Guidelines for the diagnosis and management of COPD in the Borough of City and Hackney Updated December 2015 Adapted by: Miss Hetal Dhruve, Specialist Pharmacist Respiratory Medicine, City and

More information

Asthma Prescribing Guidelines Adults and Children over 12 years

Asthma Prescribing Guidelines Adults and Children over 12 years South Staffordshire Area Prescribing Group Asthma Prescribing Guidelines Adults and Children over 12 years Inhaler choices in this guideline are different from previous versions produced by the APG. It

More information

Medicines Management of Chronic Obstructive Pulmonary Disease (COPD)

Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)

More information

Before prescribing for COPD management, the patient should have had appropriate assessment, including spirometry, as per NICE guidelines.

Before prescribing for COPD management, the patient should have had appropriate assessment, including spirometry, as per NICE guidelines. Formulary Guidance for Management of COPD patients Before prescribing for COPD management, the patient should have had appropriate assessment, including spirometry, as per NICE guidelines. For inhaler

More information

New inhaled drugs for asthma & COPD: integration into UK practice

New inhaled drugs for asthma & COPD: integration into UK practice New inhaled drugs for asthma & COPD: integration into UK practice Hasanin Khachi Lead Pharmacist - Respiratory Medicine Joint Chair UKCPA Respiratory Group Barts Health NHS Trust 30 th September 2014 Outline

More information

Chronic Obstructive Pulmonary Disease (COPD) Clinician Guide AUGUST 2016

Chronic Obstructive Pulmonary Disease (COPD) Clinician Guide AUGUST 2016 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Chronic Obstructive Pulmonary Disease (COPD) Clinician Guide AUGUST 2016 Introduction The 2016 KP National Chronic Obstructive Pulmonary Disease

More information

NHS Dumfries and Galloway Guide to inhalers: Comparison of current inhaled therapies for Asthma and COPD.

NHS Dumfries and Galloway Guide to inhalers: Comparison of current inhaled therapies for Asthma and COPD. NHS Dumfries and Galloway Guide to inhalers: Comparison of current inhaled therapies for Asthma and. LABAs (Long acting Beta2agonist) Formoterol 12 micrograms (Easyhaler formoterol) Other non-formulary

More information

At-A-Glance Outpatient Management Reference for Chronic Obstructive Pulmonary Disease (COPD)

At-A-Glance Outpatient Management Reference for Chronic Obstructive Pulmonary Disease (COPD) At-A-Glance Outpatient Management Reference for Chronic Obstructive Pulmonary Disease (COPD) BASED ON THE GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT AND PREVENTION OF COPD GLOBAL INITIATIVE FOR CHRONIC

More information

Hertfordshire Treatment Guidelines for COPD without Asthma Supporting Information (for COPD without asthma follow asthma guidelines)

Hertfordshire Treatment Guidelines for COPD without Asthma Supporting Information (for COPD without asthma follow asthma guidelines) Hertfordshire Treatment Guidelines for COPD without Asthma Supporting Information (for COPD without asthma follow asthma guidelines) This document provides further background information to support the

More information

ASTHMA TREATMENT GUIDELINES

ASTHMA TREATMENT GUIDELINES ASTHMA TREATMENT GUIDELINES Definition: Asthma is a chronic inflammatory respiratory disease. It can affect people of any age, but often starts in childhood. It is characterised by attacks (also known

More information

Service Specification

Service Specification Service Specification Spirometry in Primary Care Date: February 2011 Document Reference: Service Specification (V4.0) Contents: Section Page 1 Definition of service 3 2 Training 4 3 Reporting / Monitoring

More information

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic. bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.

More information

Treatment options for patients with COPD have increased

Treatment options for patients with COPD have increased Newly-subsidised medicines for the treatment of patients with COPD Subsidy changes for medicines used to treat patients with COPD came into effect on March 1, 2016. In this article we discuss how these

More information

At- A- Glan ce Ou tpatien t Man agem en t R eferen ce for Ch ron ic Obstru ctiv e P u lm on ary Disease (COP D)

At- A- Glan ce Ou tpatien t Man agem en t R eferen ce for Ch ron ic Obstru ctiv e P u lm on ary Disease (COP D) At- A- Glan ce Ou tpatien t Man agem en t R eferen ce for Ch ron ic Obstru ctiv e P u lm on ary Disease (COP D) Based on the GloBal strategy for diagnosis, ManaGMent and Prevention of CoPd GloBal inititiative

More information

Respiratory Inhalers. Identification Guide Version 2

Respiratory Inhalers. Identification Guide Version 2 Respiratory Inhalers Identification Guide Version 2 230801 This booklet has been produced by NHS Greater Glasgow and Clyde together with the following companies, Almirall, AstraZeneca, Boehringer Ingelheim

More information

Dr GH Kaye-Eddie Helen Joseph Hospital Pulmonology

Dr GH Kaye-Eddie Helen Joseph Hospital Pulmonology Dr GH Kaye-Eddie Helen Joseph Hospital Pulmonology Introduction Definitions Impact of Exacerbations Assessment of COPD Management of COPD Management of Acute Exacerbations Prevention of Exacerbations COPD

More information

Subsidised Inhalers for Asthma or COPD New Zealand March SABA Short-Acting Beta2 Agonists

Subsidised Inhalers for Asthma or COPD New Zealand March SABA Short-Acting Beta2 Agonists SALBUTAMOL 100mcg/puff SABA Short-Acting Beta2 Agonists TERBUTALINE SALBUTAMOL nebuliser solution 2.5mg/2.5mL nebule 5mg/2.5mL nebule Respigen SalAir Salamol Ventolin Bricanyl Turbuhaler Asthalin SAMA

More information

Management of exacerbations in chronic obstructive pulmonary disease in Primary Care

Management of exacerbations in chronic obstructive pulmonary disease in Primary Care Management of exacerbations in chronic obstructive pulmonary disease in Primary Care Acute exacerbations of chronic obstructive pulmonary disease (COPD) are associated with significant morbidity and mortality.

More information

9/22/2015. Putting COPD Guidelines into Practice for MNACVPR CONFLICT OF INTEREST OBJECTIVES

9/22/2015. Putting COPD Guidelines into Practice for MNACVPR CONFLICT OF INTEREST OBJECTIVES Putting COPD Guidelines into Practice for MNACVPR by Scott Cerreta, BS, RRT Director of Education www.copdfoundation.org scerreta@copdfoundation.org CONFLICT OF INTEREST I have no financial conflict of

More information

MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE MANAGEMENT OF CHRONC OBSTRUCTVE PULMONARY DSEASE [2 nd Edition] QUCK REFERENCE FOR HEALTHCARE PROVDERS Ministry of Health Malaysia Academy of Medicine Malaysia Malaysian Thoracic Society MANAGEMENT OF

More information

Drugs Used in Asthma and COPD

Drugs Used in Asthma and COPD Drugs Used in Asthma and COPD Charts 1 and 2 show trends in prescribing for asthma and chronic obstructive pulmonary disease (COPD). Although the recorded prevalence of asthma is higher (5.4% of registered

More information

COPD: Current Medical Therapy

COPD: Current Medical Therapy COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for

More information

COPD RESOURCE PACK SECTION 2. Initiating a COPD Clinic: Protocol & Assessment

COPD RESOURCE PACK SECTION 2. Initiating a COPD Clinic: Protocol & Assessment COPD RESOURCE PACK SECTION 2 Initiating a COPD Clinic: Protocol & Assessment In this section: 1. Initiating a chronic disease management clinic 2. Equipment for a COPD clinic 3. Primary care chronic obstructive

More information

Chronic Obstructive Pulmonary Disease (COPD) Management

Chronic Obstructive Pulmonary Disease (COPD) Management DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Chronic Obstructive Pulmonary Disease (COPD) Management Diagnosis of COPD should be considered in patients over the age of 35 who have a risk factor (generally

More information

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD) Chronic Obstructive Pulmonary Disease (COPD) October 9, 2016 Chicago, IL COPD (Chronic obstructive pulmonary disease) is a major cause of mortality and morbidity in the United States. Alarmingly, COPD

More information

COPD MANAGEMENT IN PRIMARY CARE Where are we now?

COPD MANAGEMENT IN PRIMARY CARE Where are we now? COPD MANAGEMENT IN PRIMARY CARE 2015. Where are we now? For your delight and delectation Why COPD? Patient-centred management What s new in pharmacotherapy.? Why bother? Chronic bronchitis with accompanying

More information

Update in COPD. MeiLan Han, MD MS Associate Professor University of Michigan Division of Pulmonary and Critical Care

Update in COPD. MeiLan Han, MD MS Associate Professor University of Michigan Division of Pulmonary and Critical Care Update in COPD MeiLan Han, MD MS Associate Professor University of Michigan Division of Pulmonary and Critical Care Objectives Burden of disease: Understand the need for early recognition, prevention,

More information

GINA At-A-Glance Asthma Management Reference

GINA At-A-Glance Asthma Management Reference GINA At-A-Glance Asthma Management Reference Updated 2014 Please refer to the Global Strategy for Asthma Management and Prevention (updated 2014) - www.ginasthma.org Global Initiative for Asthma DEFINITION

More information

CHRONIC OBSTRUCTIVE PULMONARY DISEASE CLINICAL PRACTICE GUIDELINES

CHRONIC OBSTRUCTIVE PULMONARY DISEASE CLINICAL PRACTICE GUIDELINES Risk Definition Components of COPD Goals Medication Reconciliation Diagnosis CHRONIC OBSTRUCTIVE PULMONARY DISEASE CLINICAL PRACTICE GUIDELINES Reviewed and approved 5/2014 COPD, a common preventable and

More information

COPD Patient Care Plan: Healthcare Provider Checklists for Quality Care in COPD. How to Use Your Checklist

COPD Patient Care Plan: Healthcare Provider Checklists for Quality Care in COPD. How to Use Your Checklist COPD Patient Care Plan: Healthcare Provider Checklists for Quality Care in COPD How to Use Your Checklist The COPD Patient Care Plan is a brief tool intended to facilitate patient assessment, patient education,

More information

Guidance to support the stepwise review of combination inhaled corticosteroid therapy for adults ( 18yrs) in asthma

Guidance to support the stepwise review of combination inhaled corticosteroid therapy for adults ( 18yrs) in asthma Guidance to support the stepwise review of combination inhaled corticosteroid therapy for adults ( 18yrs) in asthma Important Complete asthma control needs to be achieved for at least 12 weeks before attempting

More information

SUMMARY OF RECOMMENDATIONS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

SUMMARY OF RECOMMENDATIONS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) SUMMARY OF RECOMMENDATIONS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) Diagnosis and diagnostic tools Recommendation 1 Diagnosis of COPD (IV) It is recommended that spirometry should be performed

More information

Pathway for Diagnosing COPD

Pathway for Diagnosing COPD Pathway for Diagnosing Visit 1 Registry Clients at Risk Patient presents with symptoms suggestive of Exertional breathlessness Chronic cough Regular sputum production Frequent bronchitis ; wheeze Occupational

More information

COPD and New Devices. Genuair Device TREATMENT OPTIONS. September 2015

COPD and New Devices. Genuair Device TREATMENT OPTIONS. September 2015 September 2015 COPD and New Devices In Ontario, Chronic Obstructive Pulmonary Disorder (COPD) is a degenerative lung disorder that causes the airtubes in sufferers to narrow. This narrowing limits airflow

More information

At-A-Glance Outpatient Management Reference for Chronic Obstructive Pulmonary Disease (COPD)

At-A-Glance Outpatient Management Reference for Chronic Obstructive Pulmonary Disease (COPD) At-A-Glance Outpatient Management Reference f Chronic Obstructive Pulmonary Disease (COPD) BASED ON THE GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT AND PREVENTION OF COPD GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE

More information

University Of Jordan Faculty Of Pharmacy. Pharmacotherapy 2. Sheet number: 9 Price:. 1 P a g e

University Of Jordan Faculty Of Pharmacy. Pharmacotherapy 2. Sheet number: 9 Price:. 1 P a g e University Of Jordan Faculty Of Pharmacy Pharmacotherapy 2 Sheet number: 9 Price:. 1 P a g e COPD, Last time we said that COPD patients are separated into four categories, depending on the severity of

More information

Medicines Management of Chronic Obstructive Pulmonary Disease (COPD)

Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) and Reena Rabheru-Dodhy (Merton CCG)

More information

Medicines Optimisation: Helping & supporting your patients to reach their respiratory treatment goals

Medicines Optimisation: Helping & supporting your patients to reach their respiratory treatment goals Outline Medicines Optimisation: Helping & supporting your patients to reach their respiratory treatment goals Toby Capstick (toby.capstick@leedsth.nhs.uk) Lead Respiratory Pharmacist Leeds Teaching Hospitals

More information

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD) East Cheshire NHS Trust Mid Cheshire Hospitals NHS Foundation Trust Central and Eastern Cheshire Primary Care Trust Chronic Obstructive Pulmonary Disease (COPD) Issued: - November 2011 For Review: - November

More information

Latest Guidelines for COPD Treatment Evaluation. by Scott Cerreta, BS, RRT Director of Education

Latest Guidelines for COPD Treatment Evaluation. by Scott Cerreta, BS, RRT Director of Education Latest Guidelines for COPD Treatment Evaluation by Scott Cerreta, BS, RRT Director of Education www.copdfoundation.org CONFLICT OF INTEREST I have no financial conflict of interest that relates to this

More information

SOUTHERN DERBYSHIRE Nebuliser Guidelines

SOUTHERN DERBYSHIRE Nebuliser Guidelines Controlled Document Ref: G053 Issue: 1 Folder Section: 15 - Respiratory Approval Date: March 2010 Review Date: March 2012 SOUTHERN DERBYSHIRE Nebuliser Guidelines For patients with chronic respiratory

More information

Table 1: equivalences and costs of various inhalers in COPD

Table 1: equivalences and costs of various inhalers in COPD Title of Project: NHS Dumfries & Galloway Respiratory Bundle COPD: Inhaled steroid review April 2015 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and

More information

COPD. Case Study Feedback. bpac nz better medicine

COPD. Case Study Feedback. bpac nz better medicine COPD Case Study Feedback bpac nz better medicine Contents COPD Case Study... 2 Results with GP panel comments... 4 Review by Respiratory Physician - Professor Ian Town... 7 Individualised Feedback bpac

More information

Self-management plan for COPD

Self-management plan for COPD Sheffield Clinical Commissioning Group Sheffield Teaching Hospitals NHS Foundation Trust Self-management plan for COPD This is your personal management plan The aim of the plan is to help you have better

More information

Croydon CCG Recommended Inhaler Devices Quick Reference Guide

Croydon CCG Recommended Inhaler Devices Quick Reference Guide Croydon CCG Inhaler Devices Quick Reference Guide Name* Class Inhaler Type Licensed for Asthma

More information

Berkshire East Respiratory Guidelines

Berkshire East Respiratory Guidelines Berkshire East Respiratory Guidelines This is an update of guidelines which had previously have been drawn up following discussions at the East Berkshire Respiratory Group. This multidisciplinary group

More information

Chronic lung disease in adults

Chronic lung disease in adults Includes COPD, bronchiectasis, some persistent asthma. More than one can be present in same person. Diagnosis clinical history, lung function tests (spirometry), x-ray, CT scan. First assessment Ask About

More information

Asthma Summary Guideline for Adults and over 12s

Asthma Summary Guideline for Adults and over 12s Asthma Summary Guideline for Adults and over 12s Lesley Davey Staffordshire and Lancashire CSU Date March 2014 (Review date) March 2017 0 VERSION CONTROL Version Number Date Amendments made 1 1/12/14 Reviewed

More information

Chronic Obstructive Pulmonary Disease (COPD) Exacerbation. Protocol in Primary Care for South Kent CCG

Chronic Obstructive Pulmonary Disease (COPD) Exacerbation. Protocol in Primary Care for South Kent CCG Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Protocol in Primary Care for South Kent CCG NHS South Kent Coast CCG, Council Offices, White Cliffs Business Park, Dover CT16 3PJ T.030004 24700

More information

Chronic obstructive pulmonary disease (COPD)

Chronic obstructive pulmonary disease (COPD) Chronic obstructive pulmonary disease (COPD) Chronic obstructive pulmonary disease (COPD) is the name for a group of lung diseases including chronic bronchitis, emphysema and chronic obstructive airways

More information

Chronic obstructive pulmonary disease. Costing report. Implementing NICE guidance

Chronic obstructive pulmonary disease. Costing report. Implementing NICE guidance Chronic obstructive pulmonary disease Costing report Implementing NICE guidance February 2011 NICE clinical guideline 101 National costing report: chronic obstructive pulmonary disease 1 of 30 This costing

More information

Spirometry: Performance and Interpretation. A Guide for General Practitioners

Spirometry: Performance and Interpretation. A Guide for General Practitioners Irish Thoracic Society Spirometry: Performance and Interpretation A Guide for General Practitioners Dr. Terry O Connor, Consultant Respiratory Physician, Mercy University Hospital, Cork Dr. Pat Manning,

More information

A. Chronic inflammation from repeated exposure to noxious particles and gases

A. Chronic inflammation from repeated exposure to noxious particles and gases CHAPTER 15. CHRONIC OBSTRUCTIVE PULMONARY DISEASE SELF-ASSESSMENT QUESTIONS 1. All of the following play a role in the pathophysiology of COPD except: A. Chronic inflammation from repeated exposure to

More information

National Chronic Obstructive Pulmonary Disease (COPD) primary care audit (Wales) 2015

National Chronic Obstructive Pulmonary Disease (COPD) primary care audit (Wales) 2015 National Chronic Obstructive Pulmonary Disease (COPD) primary care audit (Wales) 2015 Analysis Methodology Introduction Data from two sources was used for the production of the report. The first source

More information

COPD RESOURCE PACK SECTION 11. Fife Integrated COPD Care Pathways

COPD RESOURCE PACK SECTION 11. Fife Integrated COPD Care Pathways COPD RESOURCE PCK SECTION 11 Fife Integrated COPD Care Pathways In this section: 1. COPD Guidance treatment at each stage of the disease 2. Overview of Respiratory (COPD) Integrated Pathway 3. Chronic

More information

Pulmonary Rehabilitation in Newark and Sherwood

Pulmonary Rehabilitation in Newark and Sherwood Pulmonary Rehabilitation in Newark and Sherwood With exception of smoking cessation pulmonary rehabilitation is the single most effective intervention for any patient with COPD. A Cochrane review published

More information

Asthma & COPD: Asthma and chronic obstructive pulmonary disease. Clearing the Air. John s case. Pathophysiology

Asthma & COPD: Asthma and chronic obstructive pulmonary disease. Clearing the Air. John s case. Pathophysiology Asthma & COPD: Clearing the Air Alan Kaplan, MD, CCFP(EM) As presented at Primary Care Today, Toronto (May 5, 2005). Asthma and chronic obstructive pulmonary disease (COPD) are the two most common obstructive

More information

RESEARCH UPDATE BULLETIN January 2014

RESEARCH UPDATE BULLETIN January 2014 RESEARCH UPDATE BULLETIN January 2014 Exclusive to COPD Therapy Trends clients, Impact Assessments are dynamic analyst bulletins evaluating the impact of events over the next 12 months. Impact Assessments

More information

Medication and Devices for Chronic Obstructive Pulmonary Disease (COPD)

Medication and Devices for Chronic Obstructive Pulmonary Disease (COPD) Medication and Devices for Chronic Obstructive Pulmonary Disease (COPD) Patients with COPD take a wide variety of medicines to manage their symptoms these include: Inhaled Short Acting Bronchodilators

More information

RES/006/APR16/AR. Speaker : Dr. Pither Sandy Tulak SpP

RES/006/APR16/AR. Speaker : Dr. Pither Sandy Tulak SpP RES/006/APR16/AR Speaker : Dr. Pither Sandy Tulak SpP Definition of Asthma (GINA 2015) Asthma is a common and potentially serious chronic disease that imposes a substantial burden on patients, their families

More information

ASTHMA TREATMENT GUIDE (ADULTS)

ASTHMA TREATMENT GUIDE (ADULTS) ASTHMA TREATMENT GUIDE (ADULTS) The SIGN/BTS guideline provides a wide range of information and guidance on the treatment of patients with asthma. http://sign.ac.uk/guidelines/fulltext/101/ NHS Lanarkshire

More information

CLINICAL GUIDELINE FOR THE MANAGEMENT OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD 1. Aim/Purpose of this Guideline

CLINICAL GUIDELINE FOR THE MANAGEMENT OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD 1. Aim/Purpose of this Guideline CLINICAL GUIDELINE FOR THE MANAGEMENT OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD 1. Aim/Purpose of this Guideline The guidance provides advice on the diagnosis of COPD and the

More information

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic. bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.

More information

Appendix G: Sample COPD Assessment Form

Appendix G: Sample COPD Assessment Form Nursing Care of Dyspnea: The 6th Vital Sign in Individuals with Chronic Obstructive Pulmonary Disease (COPD) Appendix G: Sample COPD Assessment Form CHRONIC OBSTRUCTIVE PULMONARY DISEASE CLINIC RETURN

More information

Chronic asthma: management

Chronic asthma: management Chronic asthma: management NICE guideline: short version Draft for consultation, December 0 This guideline covers managing chronic asthma in adults, young people and children. It aims to improve asthma

More information

Useful contacts/agencies. Self Management Plan: Information and Advice To help you manage your COPD And what to do if you feel unwell

Useful contacts/agencies. Self Management Plan: Information and Advice To help you manage your COPD And what to do if you feel unwell Useful contacts/agencies BLF (British Lung Foundation) Asthma UK http://www.blf.org.uk http://www.asthma.org.uk Self Management Plan: Information and Advice To help you manage your COPD And what to do

More information

Chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease Issue date: June 2010 Chronic obstructive pulmonary disease Management of chronic obstructive pulmonary disease in adults in primary and secondary care This is an update of NICE clinical guideline 12 Developed

More information

Self-Management Plan for COPD

Self-Management Plan for COPD South Tyneside NHS Foundation Trust Self-Management Plan for COPD This is your personal management plan. The aim of this plan is to help you have better control of your chronic obstructive pulmonary disease

More information

On completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children

On completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children 7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists

More information

Disclosure. Meet TK. Mortality. Dr. Wheeler has nothing to disclose. 3/25/2013. Objectives: An exacerbation is. COPD Management: Exacerbation

Disclosure. Meet TK. Mortality. Dr. Wheeler has nothing to disclose. 3/25/2013. Objectives: An exacerbation is. COPD Management: Exacerbation COPD Management: Exacerbation Disclosure Dr. Wheeler has nothing to disclose. Meet TK Objectives: 1 Discuss guidelines and treatment strategies for exacerbations 2 Discuss the criteria for hospitalization

More information

Medicines Management of Asthma Guidelines for Primary Care

Medicines Management of Asthma Guidelines for Primary Care Medicines Management of Guidelines for Primary Care Version 1: September 2011 Updated: October 2013 Updated: June 2015 Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s

More information

Clinical Practice Guideline: Asthma

Clinical Practice Guideline: Asthma Clinical Practice Guideline: Asthma INTRODUCTION A critical aspect of the diagnosis and management of asthma is the precise and periodic measurement of lung function both before and after bronchodilator

More information

Continuing Professional Pharmacy Development (CPPD) CPPD calendar. Facebook: QUCPPD

Continuing Professional Pharmacy Development (CPPD) CPPD calendar. Facebook: QUCPPD Continuing Professional Pharmacy Development (CPPD) CPPD 2013-2014 calendar Facebook: QUCPPD Continuing Professional Pharmacy Development (CPPD) Essentials in Asthma Management: The Action Plan 30 Oct

More information

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic. bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.

More information

Enabling Patient health Improvements though COPD medicines optimisation (EPIC)

Enabling Patient health Improvements though COPD medicines optimisation (EPIC) Enabling Patient health Improvements though COPD medicines optimisation (EPIC) Commissioned by NHS Leeds West CCG Contact Details: Ruth Buchan Service Development Manager Tel: 07718 192 287 Email: ruth@cpwy.org

More information

Inhaled Corticosteroid Audit

Inhaled Corticosteroid Audit Inhaled Corticosteroid Audit AIM To enable practices to review their prescribing of inhaled corticosteroids (ICS) for both asthma and / or COPD To step down the dose of ICS where clinically appropriate

More information

Prevention of Acute COPD exacerbations

Prevention of Acute COPD exacerbations December 3, 2015 Prevention of Acute COPD exacerbations George Pyrgos MD 1 Disclosures No funding received for this presentation I have previously conducted clinical trials with Boehringer Ingelheim. Principal

More information

Respiratory and Asthma Medications. Guidance on Respiratory and Asthma Medications (applicable from 01 January 2017) Beta-2 agonists:

Respiratory and Asthma Medications. Guidance on Respiratory and Asthma Medications (applicable from 01 January 2017) Beta-2 agonists: Respiratory and Asthma Medications Guidance on Respiratory and Asthma Medications (applicable from 01 January 2017) The following guide lists common Respiratory and Asthma Medications and whether they

More information

Inhaler Use in Care Homesprompts for educational session to care home staff. Community Pharmacy Enhanced Service to Care Homes

Inhaler Use in Care Homesprompts for educational session to care home staff. Community Pharmacy Enhanced Service to Care Homes Inhaler Use in Care Homesprompts for educational session to care home staff Community Pharmacy Enhanced Service to Care Homes Objective To improve the outcomes for patients in care homes with respiratory

More information

Your COPD self-management plan

Your COPD self-management plan Your details Name: Date of birth: NHS No: GP Name & tel: Next of kin: Page 1 Contents Page What is a self-management plan? 3 What to do when you are well and stable 3 What is a flare-up (exacerbation)?

More information

COPD -Management of stable disease WONCA meeting Istanbul October 2015

COPD -Management of stable disease WONCA meeting Istanbul October 2015 COPD -Management of stable disease WONCA meeting Istanbul October 2015 IPCRG 2007 Svein Høegh Henrichsen Oslo, Norway Principles of management in stable COPD Patient education Smoking cessation Non-pharmacologic

More information

Diagnosis, Treatment and Management of Asthma

Diagnosis, Treatment and Management of Asthma Diagnosis, Treatment and Management of Asthma Asthma is a complex disorder characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation.

More information

Asthma and COPD. Trends in Prescribing of Drugs for Asthma and COPD in General Practice in England (Chart 1)

Asthma and COPD. Trends in Prescribing of Drugs for Asthma and COPD in General Practice in England (Chart 1) Asthma and COPD This review will focus on the most recent evidence regarding the safety of currently recommended options for treating chronic asthma and exacerbations in chronic obstructive pulmonary disease

More information

Bryan Krajicek, MD Pulmonary Medicine i Specialists, PC Assistant Professor of Medicine Creighton University School of Medicine

Bryan Krajicek, MD Pulmonary Medicine i Specialists, PC Assistant Professor of Medicine Creighton University School of Medicine COPD Update Bryan Krajicek, MD Pulmonary Medicine i Specialists, PC Assistant Professor of Medicine Creighton University School of Medicine Disclosures Dr. Krajicek has no financial interest that would

More information

Clinical Practice Guideline for the Management of Asthma in Children and Adults

Clinical Practice Guideline for the Management of Asthma in Children and Adults Clinical Practice Guideline for the Management of Asthma in Children and Adults Assessment: A critical aspect of the diagnosis and management of asthma is the precise and periodic measurement of lung function

More information

The optimal management of patients with COPD

The optimal management of patients with COPD The optimal management of patients with COPD Part 1: The diagnosis 12 Chronic obstructive pulmonary disease (COPD) affects approximately one in seven New Zealanders aged over 40 years, 1 and is the fourth

More information

¹GOLDStages of COPD defined by Spirometry are as follows: Stage 3: Severe. FEV1 30% but< 50% Stage 4: Very Severe: FEV1 <30% predicted

¹GOLDStages of COPD defined by Spirometry are as follows: Stage 3: Severe. FEV1 30% but< 50% Stage 4: Very Severe: FEV1 <30% predicted NPA Primary Care Committee The Purpose of the Chronic Obstructive Pulmonary Disease Model Practice The 2012 PACE Chronic Obstructive Pulmonary Disease Model Practice provides relevant diagnostic and treatment

More information

Objectives. The Impact of COPD in the United States. Risk Factors for COPD. Pathophysiology of COPD

Objectives. The Impact of COPD in the United States. Risk Factors for COPD. Pathophysiology of COPD Objectives Upon completion of this activity, participants will be able to: Identify diagnostic challenges in Understand evidence-based guidelines recommendations for assessment of Recognize appropriate

More information

28/04/2015. Dr. Brandie Walker March 30, Disclosures

28/04/2015. Dr. Brandie Walker March 30, Disclosures Dr. Brandie Walker March 30, 2015 Disclosures 1 Objectives 1. To Define the Asthma COPD Overlap Syndrome 2. Understand why it is important to distinguish ACOS from both Asthma and COPD 3. How will ACOS

More information

Sheri Stensland, PharmD, AE-C, FAPhA Associate Professor of Pharmacy Practice Midwestern University/Walgreens

Sheri Stensland, PharmD, AE-C, FAPhA Associate Professor of Pharmacy Practice Midwestern University/Walgreens Sheri Stensland, PharmD, AE-C, FAPhA Associate Professor of Pharmacy Practice Midwestern University/Walgreens Sheri Stensland declares no conflicts of interest, real or apparent, and no financial interests

More information

Making Sense of New Inhalers for COPD and Asthma. Eloise Harman MD Malcom Randall VAMC

Making Sense of New Inhalers for COPD and Asthma. Eloise Harman MD Malcom Randall VAMC Making Sense of New Inhalers for COPD and Asthma Eloise Harman MD Malcom Randall VAMC Inhaled Drugs for COPD/Asthma Beta agonists Anticholinergics (anti-muscarinic) Corticosteroids Short Acting Beta Agonists(Rescue)

More information

Best Practices in the Prevention & Management of COPD

Best Practices in the Prevention & Management of COPD Best Practices in the Prevention & Management of COPD David Beuther, MD, FCCP Chief Medical Information Officer Associate Professor of Medicine Division of Pulmonary and Critical Care Medicine National

More information

Objective: To correctly identify children with asthma early, and begin management that allows full activity and prevents severe exacerbations.

Objective: To correctly identify children with asthma early, and begin management that allows full activity and prevents severe exacerbations. Asthma Diagnosis and Preventive Management in Children Originally Approved: March 2014 Last Updated: March 2014 Topic Owner: Cathy Pew MD (cpew@uw.edu) Guidelines Reviewed: 1. NHLBI 2007 Expert Panel Report

More information

Inhaler Use in Older COPD Patients. Disclosures. Objectives 6/4/2014

Inhaler Use in Older COPD Patients. Disclosures. Objectives 6/4/2014 Inhaler Use in Older COPD Patients Amber M. Hutchison, PharmD, BCPS Assistant Clinical Professor Auburn University Harrison School of Pharmacy Disclosures Neither I, nor my spouse, have relationships with

More information

COPD PROTOCOL CELLO. Leiden

COPD PROTOCOL CELLO. Leiden COPD PROTOCOL CELLO Leiden May 2011 1 Introduction This protocol includes an explanation of the clinical picture, diagnosis, objectives and medication of COPD. The Cello way of working can be viewed on

More information